TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
3.980
-0.030 (-0.75%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer.

The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma.

The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers.

TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

TriSalus Life Sciences, Inc.
TriSalus Life Sciences logo
Country United States
Founded 2010
Industry Medical Devices
Sector Healthcare
Employees 112
CEO Mary Szela

Contact Details

Address:
6272 West 91st Avenue
Westminster, Colorado 80031
United States
Phone 303 442 1222
Website trisaluslifesci.com

Stock Details

Ticker Symbol TLSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001826667
CUSIP Number 89680M101
ISIN Number US89680M1018
Employer ID 85-3009869
SIC Code 3841

Key Executives

Name Position
Mary T. Szela B.S.N., M.B.A. Chief Executive Officer, President and Director
Sean Edward Murphy Chief Financial Officer and Director
Lori Ann Santamaria Vice President of Operations
Dr. Bryan F. Cox Ph.D. Chief Scientific and Manufacturing Officer
James E. Young Senior Vice President of Investor Relations and Treasurer
Dr. Richard B. Marshak M.B.A., MBA, VMD Senior Vice President of Corporate Development and Strategy
Jennifer L. Stevens J.D. Chief Regulatory Officer
Jodi Devlin President of Commercial Operations

Latest SEC Filings

Date Type Title
Nov 1, 2024 8-K Current Report
Oct 29, 2024 S-3 Registration statement under Securities Act of 1933
Oct 29, 2024 POS AM Post-Effective amendments for registration statement
Oct 29, 2024 POS AM Post-Effective amendments for registration statement
Oct 29, 2024 POS AM Post-Effective amendments for registration statement
Oct 21, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 15, 2024 424B3 Prospectus
Aug 15, 2024 424B3 Prospectus
Aug 15, 2024 424B3 Prospectus
Aug 15, 2024 8-K Current Report